Dominic Piscitelli Sells 52,000 Shares of Oric Pharmaceuticals (NASDAQ:ORIC) Stock

26 Feb 2026, 17:58 by Scott Moore · The Cerbat Gem

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC – Get Free Report) CFO Dominic Piscitelli sold 52,000 shares of the firm’s stock in a transaction dated Tuesday, February 24th. The stock was sold at an average price of $13.51, for a total transaction of $702,520.00. Following the sale, the chief financial officer owned 68,148 shares of the company’s stock, valued at $920,679.48. This trade represents a 43.28% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Dominic Piscitelli also recently made the following trade(s):

On Tuesday, December 16th, Dominic Piscitelli sold 10,720 shares of Oric Pharmaceuticals stock. The shares were sold at an average price of $9.06, for a total transaction of $97,123.20.

Oric Pharmaceuticals Trading Up 0.7%

Shares of ORIC stock traded up $0.10 during trading hours on Thursday, hitting $13.50. 1,043,043 shares of the company were exchanged, compared to its average volume of 1,709,341. The firm has a fifty day simple moving average of $10.17 and a 200 day simple moving average of $10.96. Oric Pharmaceuticals, Inc. has a 52-week low of $3.90 and a 52-week high of $14.93. The stock has a market capitalization of $1.35 billion, a price-to-earnings ratio of -8.88 and a beta of 1.35.

Oric Pharmaceuticals (NASDAQ:ORIC – Get Free Report) last posted its quarterly earnings data on Monday, February 23rd. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.04. Sell-side analysts anticipate that Oric Pharmaceuticals, Inc. will post -2.17 EPS for the current year.

Oric Pharmaceuticals News Roundup

Here are the key news stories impacting Oric Pharmaceuticals this week:

Positive Sentiment: Q4 earnings beat consensus (reported EPS -$0.30 vs. -$0.34 expected), which likely sparked buyer interest and helped lift the stock. Read More.
Positive Sentiment: HC Wainwright raised Q1–Q4 and FY2026 EPS estimates (improving loss trajectory) and reiterated a Buy with a $25 price target (up from $23), giving investors a higher valuation anchor. This analyst upgrade and estimate lift are supportive for further upside. Read More.
Positive Sentiment: Broker consensus/coverage implies significant upside — a Zacks compilation notes the mean analyst price target implies roughly ~58% upside, which can attract momentum buying from growth/biotech investors. Read More.
Positive Sentiment: Wedbush issued an Outperform rating, adding to the positive analyst momentum behind the shares. Read More.
Neutral Sentiment: Recent market writeups reassessing ORIC after Phase 1b data and a $264M capital raise discuss valuation and runway; the capital raise reduces near‑term financing risk but may be dilutionary — investors will parse data and dilution when setting targets. Read More.
Negative Sentiment: CFO Dominic Piscitelli sold 52,000 shares (~43% reduction in his holdings) at ~$13.51 per share, a sizable insider sale that can cause concern for some investors about timing or liquidity needs. The transaction is disclosed in the SEC filing. Read More.

Hedge Funds Weigh In On Oric Pharmaceuticals

A number of large investors have recently modified their holdings of the company. Vanguard Group Inc. increased its holdings in Oric Pharmaceuticals by 48.8% during the 3rd quarter. Vanguard Group Inc. now owns 4,650,138 shares of the company’s stock worth $55,802,000 after acquiring an additional 1,525,445 shares during the period. Alkeon Capital Management LLC boosted its holdings in Oric Pharmaceuticals by 12.5% in the 2nd quarter. Alkeon Capital Management LLC now owns 4,504,096 shares of the company’s stock valued at $45,717,000 after purchasing an additional 500,000 shares during the period. State Street Corp grew its position in shares of Oric Pharmaceuticals by 77.1% during the 4th quarter. State Street Corp now owns 4,258,397 shares of the company’s stock valued at $34,834,000 after purchasing an additional 1,854,458 shares in the last quarter. Orbimed Advisors LLC increased its holdings in shares of Oric Pharmaceuticals by 305.0% in the third quarter. Orbimed Advisors LLC now owns 3,641,756 shares of the company’s stock worth $43,701,000 after purchasing an additional 2,742,475 shares during the period. Finally, Price T Rowe Associates Inc. MD increased its holdings in shares of Oric Pharmaceuticals by 14.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,295,122 shares of the company’s stock worth $26,955,000 after purchasing an additional 423,795 shares during the period. 95.05% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

ORIC has been the topic of a number of research reports. Wedbush restated an “outperform” rating and issued a $20.00 price objective on shares of Oric Pharmaceuticals in a research note on Tuesday. Piper Sandler initiated coverage on shares of Oric Pharmaceuticals in a research note on Wednesday, January 7th. They issued an “overweight” rating and a $22.00 target price for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Oric Pharmaceuticals in a research report on Thursday, January 22nd. JPMorgan Chase & Co. upped their price target on shares of Oric Pharmaceuticals from $17.00 to $20.00 and gave the company an “overweight” rating in a research note on Tuesday, November 18th. Finally, Wells Fargo & Company raised their price objective on shares of Oric Pharmaceuticals from $19.00 to $25.00 and gave the stock an “overweight” rating in a report on Monday, December 8th. Eleven investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Oric Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $20.20.

Check Out Our Latest Analysis on ORIC

Oric Pharmaceuticals Company Profile

(Get Free Report)

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.